Ars Technica • 4/9/2026 – 4/10/2026

A clinical trial has demonstrated that an improved gene editing process can effectively reactivate the fetal version of a hemoglobin gene for the treatment of β-Thalassaemia.
Advertisement
Stories gain Lindy status through source reputation, network consensus, and time survival.

















